title: [A case of gastric cancer with rhabdoid features showing better prognosis through S-1/CDDP chemotherapy].
abstract: Although gastric cancers(GCs)with rhabdoid features are rare, they are known to show a poorer prognosis compared with conventional GCs. Indeed, more than half of reported GCs with rhabdoid features died within 6 months after receiving any kind of initial treatment. Obviously, no effective chemotherapy has been reported. In this study, we present a case of GC with rhabdoid features which showed a better response to a chemotherapy, S-1/CDDP, and lived for over 12 months after the initial chemotherapy. A 75-year-old man was seen in our hospital for epigastralgia. Detailed examinations revealed that he had GC at Stage IV. Consequently, he underwent S-1/CDDP treatment. This treatment produced a good response for 6 months, minimizing the size of the primary tumor and eradicating distant metastases. Re-growth of the primary tumor without uprising distant metastasis was confirmed 8 months after the initialS -1/CDDP treatment, and the patient went through a gastrectomy for curative care. After surgery, a precise pathological examination revealed that the primary tumor possessed a poorly differentiated adenocarcinoma that contained tumor cells with typical rhabdoid features. In the end, the patient died of liver metastasis 13 months after the initial S-1/CDDP chemotherapy.
authors.affiliation: Department of Surgery, Kagawa-Rousai Hospital.
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Mori
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Shinichi
authors.initials: S
authors.lastname: Ishihara
authors.forename: Kouichi
authors.initials: K
authors.lastname: Mizobuchi
authors.forename: Miki
authors.initials: M
authors.lastname: Kishi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kurosaki
authors.forename: Soichiro
authors.initials: S
authors.lastname: Miyake
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Watanabe
authors.forename: Keigo
authors.initials: K
authors.lastname: Kimura
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Kokudo
authors.forename: Atsushi
authors.initials: A
authors.lastname: Muraoka
authors.forename: Akihiko
authors.initials: A
authors.lastname: Tatemoto
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nagasaka
authors.forename: Makoto
authors.initials: M
authors.lastname: Tsumura
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004338:Drug Combinations; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D018335:Rhabdoid Tumor / Q000188:drug therapy* / Q000473:pathology; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin